Clinical Trials Directory

A Phase I Investigation of IL-12 (NSC 672423)/Pulse IL-2 (Aldesleukin) in Children With Persistent and/or Refractory Neuroblastoma (13623)

Phase I trial to compare the effectiveness of interleukin-12 with or without interleukin-2 in treating young patients who have refractory or recurrent neuroblastoma. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining interleukin-2 with interleukin-12 may kill more tumor cells.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.


  • biological : recombinant interleukin-12
  • biological : aldesleukin

Phase: Phase 1


Ages Eligible For Study:

3 Years - 21 Years

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Judy Hallagan
Not Recruiting

Footer Links: